Return To Growth In Biosimilars A Priority For Biogen

Full-Year Biosimilars Revenue Expected To Be Down Versus 2021

 
• By Chloe Kent

Biogen’s biosimilars business took a hit in Q1 following pricing pressures and negative currency fluctuations, with the company now prioritizing the rebuilding of the segment.

Growth man drawing graph pen
Biogen has listed biosimilars growth as one of its priorities. • Source: Christian Horz / Alamy Stock Photo

More from Earnings

More from Business